Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06878027

Analysis of Urinary Methylation Patterns Via Liquid Biopsy as an Early Diagnosis Tool

Multicenter, observational, prospective, biological pilot study on liquid biopsy, aimed at investigating methylation profiles in relation to the early diagnosis of bladder cancer, to validate the potential of commercially available tests (e.g. BladderCARE, Bladder EpiCheck), to apply and validate tests based on targeted multi-marker or genome wide analyzes via NGS and to identify methylation profiles as a tool to infer clinical outcome.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

IRCCS National Cancer Institute "Regina Elena"

Rome, 00144, Italy

Location status: Recruiting

Location contact

Giuseppe Simone, Medical Doctor

CONTACT

[email protected]

+39 0652665005

About this study

The study has the primary objective to investigate the diagnostic capacity of methylation levels in urine samples, furthermore it has the secondary objective of applying an NGS test on the urine sample capable of evaluating the highest methylation levels comprehensive, with better analytical performance than the currently available standard on the market, leveraging targeted sequencing of multiple genes or global analysis of the whole methylome.

To describe the diagnostic performance of the methods in a real-world clinical environment and identify the characteristic methylation profiles capable of stratifying patients with different prognoses, and finally to explore the potential economic impact of applying such tests as tools alternatives to conventional practices.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient group

  • age ≥ 18 years
  • proven diagnosis of bladder cancer (infiltrating muscle or non-infiltrating muscle)
  • performance status (PS) 0-1
  • ability to follow the procedures established by the study
  • written consent for participation in the study and data processing

group of healthy subjects

  • age ≥ 18 years
  • ability to follow the procedures established by the study
  • written consent for participation in the study and data processing

Exclusion criteria

Patient group

  • presence of metastatic bladder cancer
  • lack of autonomy in following the procedures established by the study

group of healthy subjects

  • previous or current clinical history associated with bladder cancer
  • diagnostic suspicion associated with tumor pathologies
  • ongoing or previous systemic oncological treatments
  • presence of inflammatory and/or autoimmune diseases related to particular conditions potentially modifying the methylation profile
  • existing pharmacological treatments (and/or any other type of treatment) that could alter the results of the analyzes conducted for the present study
  • lack of autonomy in following the procedures established by the study

Treatment and study plan

Primary outcomes

  1. Methylation state

    Time frame: 18 months

    Measurement of methylation status using the Bladder CARE test (Pangea Laboratory LLC). The test, based on quantitative PCR and evaluation of methylation status in 3 target genes, is performed on a urine sample and has reported high sensitivity (94%) and specificity (93%) values in determining the presence of bladder cancer

Study contacts

Contact information is provided by the study sponsor or research team.

Giuseppe Simone, Medical Doctor

CONTACT

[email protected]

+39 0652665005

Sponsors and collaborators

Lead sponsor

Regina Elena Cancer Institute

Other

Collaborators

  • Azienda Ospedaliera Santa Maria Degli Angeli
  • Istituto per lo Studio, la Prevenzione e la Rete Oncologica

Registry information

Official study title

Analysis of Urinary Methylation Patterns Via Liquid Biopsy as a Tool for Early Diagnosis, Non-invasive Monitoring and Prediction of Recurrence Risk in Bladder Cancer

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Mar 14, 2025
Registry last updated
Mar 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.